newsfilter
← Latest News
Business Wire·

Reata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2022, and provide an update